HomeINRLF • OTCMKTS
add
Valneva SE
Previous close
$1.98
Year range
$1.98 - $5.40
Market cap
296.75M EUR
Avg Volume
794.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 45.82M | 20.36% |
Operating expense | 13.66M | 234.94% |
Net income | -9.24M | 73.01% |
Net profit margin | -20.16 | 77.58% |
Earnings per share | -0.15 | 71.80% |
EBITDA | -12.40M | -16.52% |
Effective tax rate | 28.71% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 156.34M | -8.71% |
Total assets | 516.61M | -0.75% |
Total liabilities | 299.14M | -17.59% |
Total equity | 217.47M | — |
Shares outstanding | 140.53M | — |
Price to book | 1.28 | — |
Return on assets | -6.31% | — |
Return on capital | -7.80% | — |
Cash Flow
Net change in cash
| (EUR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -9.24M | 73.01% |
Cash from operations | -10.48M | 85.32% |
Cash from investing | -15.38M | -751.14% |
Cash from financing | 51.86M | 45.62% |
Net change in cash | 24.92M | 175.16% |
Free cash flow | -41.46M | 41.47% |
About
Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
Founded
2013
Website
Employees
700
